TET2 mutation alone was found to have no prognostic impact on event-free survival (EFS) or OS in one study.245 Similarly, TET2 mutations were detected in 19.8–23.3% of secondary AMLs, and did not influence OS.252,253 In addition, TET2 mutations occurred in 32–65% of CMML and were favorable prognostic factors,29,254–260 but were associated with poor survival in the presence of ASXL1 mutations.261 While in another study, TET2 mutations were correlated with poor survival.262 There are different types of TET2 mutations, and patients have different clinical outcomes. This evidence concerns the gene TET2 and chronic myelomonocytic leukemia.